2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Research, AML, Translational Research, MDS, MPN, CML, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2504 Identification of novel sepsis subtypes unique to adult allogeneic hematopoietic stem cell transplantation patients: A consensus k-means clustering

Mengya Yang, Qiu-Sha Huang, MD2, Lu-Lu Wang3, Yun He, MD4, Hai-Xia Fu, MD5, Xiaolu Zhu, MD6, Fengrong Wang7, Yuanyuan Zhang8, Xiao-Dong Mo, MD9, Wei Han10, yuqian Sun11, Chen-hua Yan12, Jingzhi Wang13, Huan Chen14, Yuhong Chen15, Ting-ting Han, MD16, Meng Lv17, Yao Chen, MD18, Yu Wang19, Lanping Xu, MD20, Xiaojun Huang, MD, PhD21, Xiaohui Zhang, MD22
1 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
3 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
4 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
5 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
6 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
7 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
8 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
9 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
10 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
11 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
12 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
13 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
14 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
15 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
16 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
17 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
18 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
19 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
20 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
21 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
22 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China

Introduction

Sepsis is characterized by life-threatening organ dysfunction resulting from a dysregulated and non-homeostatic host response to infection, with an overall mortality rate ranging from 26.7% to 41.9%. Among hematopoietic stem cell transplantation recipients, previous studies have reported sepsis-related mortality ranging from 30% to 90%. The clinical syndrome of sepsis encompasses a highly heterogeneous population, which is increasingly recognized as the primary obstacle to achieving positive results in clinical trials and advancing precision medicine. However, the heterogeneity of sepsis in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients remains poorly characterized.

Method

We retrospectively included 659 patients developing sepsis following allo-HSCT at Peking University People’s Hospital between 2015 and 2025. Consensus k-means clustering was used to identify sepsis subphenotypes, while 41 (6.2%) individuals with missing values in any clustering variable were excluded prior to analysis. The optimal number of clusters was determined by evaluating cumulative distribution function (CDF) curves and clinical interpretability. A total of 16 candidate variables were selected for clustering, covering demographics (age, BMI), vital signs (heart rate), disease severity (SOFA score), inflammatory markers (WBC, CRP, LDH), coagulation parameters (platelet count, PT-INR, fibrinogen, D-dimer), organ function (creatinine, total bilirubin, albumin), and hematologic indices (HB, RDW). We used Gaussian mixture model to identify different trajectories of platelet count within the first seven consecutive days after the diagnosis of sepsis. Overall survival (OS) was analyzed using the Kaplan–Meier method and log-rank test.

Results

A cohort of 618 patients was analyzed, revealing three distinct sepsis subphenotypes, designated as Clusters 1, 2, and 3. Cluster 3 (n=104) was predominantly characterized by severe coagulation dysfunction (lowest platelet count, elevated PT-INR, and D-dimer) along with multi-organ failure, and exhibited the highest SOFA scores and the poorest prognosis. Cluster 2 (n=302) showed predominantly profound leukopenia and mild pancytopenia, whereas Cluster 1 (n=212) demonstrated the mildest abnormalities. Males predominated in every subgroup, representing 61.3% of Cluster 1, 63.2% of Cluster 2, and 76.0% of Cluster 3. A comparative analysis of baseline transplant-related clinical characteristics among the subphenotypes revealed that patients in Cluster 1 had the highest incidence of acute and chronic graft-versus-host disease, as well as Epstein-Barr virus and cytomegalovirus reactivation. Conversely, Cluster 2 was associated with the lowest incidence of graft-versus-host disease and viral reactivation. Furthermore, the proportion of patients who failed to recover platelet counts within 30 days was 13.2% in Cluster 1, 20.5% in Cluster 2, and 34.6% in Cluster 3. The incidence rates of septic shock and disseminated intravascular coagulation (DIC) exhibited significant variation across the three identified clusters. Specifically, septic shock was observed in 33.3% of patients within Cluster 1, 39.1% in Cluster 2, and escalated to a notably high 70.9% in Cluster 3. Concurrently, the prevalence of DIC was 44.81% in Cluster 1, 26.49% in Cluster 2, and significantly elevated at 77.88% in Cluster 3. Kaplan-Meier analysis revealed that overall survival (OS) in Cluster 2 was significantly inferior compared to both Cluster 1 (P < 0.001) and Cluster 3 (P < 0.001); additionally, Cluster 3 demonstrated poorer OS relative to Cluster 1 (P = 0.045). We further conducted a detailed analysis of the longitudinal platelet trajectories within Cluster 3 and observed that 50.9% of patients maintained consistently low platelet levels during the first week following the onset of sepsis, while 14.4% of patients exhibited a significant and continuous decline in platelet counts.

Conclusion

This study stratified sepsis patients after allogeneic hematopoietic stem cell transplantation into three clinically meaningful subphenotypes based on multi-dimensional clinical and laboratory indicators. Combined analysis of consensus clustering subphenotypes and early platelet trajectories can effectively distinguish high-risk septic allo-HSCT recipients, which provides a novel basis for individualized risk stratification in clinical practice.

Mengya Yang: No relevant conflicts of interest to declare.